The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab vedotin-ejfv ...

A significant communication gap exists between NMIBC patients and providers, with only 18% having regular discussions about ...

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

The FDA approved enfortumab vedotin and pembrolizumab for MIBC, following a priority review of their sBLA for neoadjuvant and ...

Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin ...

The FDA approved the combination of pembrolizumab (Keytruda) and enfortumab vedotin-ejfv (Padcev) for neoadjuvant and ...

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...

Merck (MRK) announced that the U.S. FDA has approved Keytruda and Keytruda Qlex in combination with Padcev as neoadjuvant treatment and then ...

Pfizer (PFE) and Astellas Pharma (ALPMY) (ALPMY announced that the U.S. Food and Drug Administration has approved PADCEV, a Nectin-4 directed ...

Research and development expenses for the third quarter of 2025 increased to $9.6 million from $8.1 million for the prior year period. The increase was primarily due to a $0.9 million increase in ...

Overall survival data showed a 50% reduction in the risk of death with the regimen compared with surgery alone.